CNBX appoints Dr. Sanja Goldberg as CTO, replacing Dr. Eyal Ballan

CNBX Pharmaceuticals Inc.

Dr. Eyal Ballan resigned as CTO and employment ended effective July 20, 2022.
Dr. Sanja Goldberg appointed as new CTO on July 24, 2022.
Goldberg previously held senior researcher roles at Sheba Medical Center's Cancer Research Lab.
She held executive positions at Compugen and TaGeza Biopharma (VP R&D).
Goldberg earned a Ph.D. in Cell Biology from Erasmus MC, Rotterdam in 2009.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sanja Goldberg

Chief Technology Officer

CNBX · CNBX Pharmaceuticals Inc.

Effective: 2022-07-24
Filed: July 25, 2022, 7:59 PM ET

Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24 th , 2022.

Departed

Eyal Ballan

Chief Technology Officer

CNBX · CNBX Pharmaceuticals Inc.

Effective: 2022-07-20
Successor: Sanja Goldberg
Filed: July 25, 2022, 7:59 PM ET

Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20 th , 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sanja Goldberg was appointed as Chief Technology Officer at CNBX Pharmaceuticals Inc..

Action: appointed
Role: Chief Technology Officer

Exact text from the filing

Dr. Sanja Goldberg was appointed as the Company’s new Chief Technology Officer on July 24 th , 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eyal Ballan resigned as Chief Technology Officer at CNBX Pharmaceuticals Inc..

Action: resigned
Role: Chief Technology Officer

Exact text from the filing

Chief Technology Officer Dr. Eyal Ballan has resigned his position as CTO and his employment with the Company has ended effective July 20 th , 2022.

View on SEC.gov

CNBX Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-005100

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.